JP2023514784A5 - - Google Patents
Info
- Publication number
- JP2023514784A5 JP2023514784A5 JP2022550888A JP2022550888A JP2023514784A5 JP 2023514784 A5 JP2023514784 A5 JP 2023514784A5 JP 2022550888 A JP2022550888 A JP 2022550888A JP 2022550888 A JP2022550888 A JP 2022550888A JP 2023514784 A5 JP2023514784 A5 JP 2023514784A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- vivo
- radioisotope
- receptor
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981113P | 2020-02-25 | 2020-02-25 | |
| US62/981,113 | 2020-02-25 | ||
| US202062993636P | 2020-03-23 | 2020-03-23 | |
| US62/993,636 | 2020-03-23 | ||
| PCT/CA2021/050226 WO2021168567A1 (en) | 2020-02-25 | 2021-02-25 | Chelator compositions for radiometals and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514784A JP2023514784A (ja) | 2023-04-10 |
| JP2023514784A5 true JP2023514784A5 (enExample) | 2024-03-05 |
Family
ID=77490568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550888A Pending JP2023514784A (ja) | 2020-02-25 | 2021-02-25 | 放射性金属用キレート剤組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230270892A1 (enExample) |
| EP (1) | EP4110768A4 (enExample) |
| JP (1) | JP2023514784A (enExample) |
| AU (1) | AU2021226147A1 (enExample) |
| CA (1) | CA3172811A1 (enExample) |
| WO (1) | WO2021168567A1 (enExample) |
| ZA (1) | ZA202210224B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
| CA3136979A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| WO2022082312A1 (en) | 2020-10-21 | 2022-04-28 | Provincial Health Services Authority | Novel cxcr4-targeting compounds |
| CN114807636B (zh) * | 2021-12-31 | 2023-10-20 | 中国工程物理研究院核物理与化学研究所 | 一种无载体177Lu和161Tb的GMP生产方法 |
| KR20240167790A (ko) * | 2022-03-30 | 2024-11-28 | 니혼 메디피직스 가부시키가이샤 | 복합체의 제조 방법 |
| CN119325393A (zh) * | 2022-05-03 | 2025-01-17 | 北卡罗来纳大学教堂山分校 | 用于成像和治疗应用的靶向ntsr的试剂的开发 |
| CN115286697B (zh) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | 一种双重靶向化合物及其制备方法和应用 |
| WO2024235273A1 (zh) * | 2023-05-15 | 2024-11-21 | 成都社泰医疗科技有限公司 | 多靶向化合物及其应用 |
| AU2024346916A1 (en) * | 2023-09-22 | 2026-03-26 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
| WO2025156030A1 (en) * | 2024-01-25 | 2025-07-31 | The University Of British Columbia | 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same |
| WO2025171492A1 (en) * | 2024-02-14 | 2025-08-21 | Alpha-9 Oncology Inc. | Stable radiopharmaceutical compositions and uses thereof |
| WO2025194281A1 (en) * | 2024-03-22 | 2025-09-25 | Triumf Inc. | Chelator compositions for radiometals and methods of using same |
| CN118725025A (zh) * | 2024-06-04 | 2024-10-01 | 厦门稀土材料研究所 | 用于177Lu标记的三齿类酰胺酸型双功能螯合剂及其制备方法和应用 |
| WO2026000067A1 (en) * | 2024-06-24 | 2026-01-02 | Alpha-9 Oncology Inc. | Stable radiopharmaceutical compositions and uses thereof |
| WO2026096892A1 (en) * | 2024-11-01 | 2026-05-07 | Ratio Therapeutics, Inc. | Somatostatin binding compositions and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6517814B2 (en) * | 2001-01-09 | 2003-02-11 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants useful for metallopharmaceuticals |
| CN102212042A (zh) * | 2011-04-18 | 2011-10-12 | 北京师范大学 | 一种四氮杂冠醚的合成方法 |
| CN104151367B (zh) * | 2014-08-06 | 2016-05-04 | 北京师范大学 | 一种稀土镧配合物及其合成方法 |
| CN104151368B (zh) * | 2014-08-06 | 2016-05-04 | 北京师范大学 | 一种稀土铕配合物及其合成方法 |
| CA3100868A1 (en) * | 2018-05-23 | 2019-11-28 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
-
2021
- 2021-02-25 US US17/801,777 patent/US20230270892A1/en active Pending
- 2021-02-25 JP JP2022550888A patent/JP2023514784A/ja active Pending
- 2021-02-25 WO PCT/CA2021/050226 patent/WO2021168567A1/en not_active Ceased
- 2021-02-25 EP EP21760355.4A patent/EP4110768A4/en active Pending
- 2021-02-25 CA CA3172811A patent/CA3172811A1/en active Pending
- 2021-02-25 AU AU2021226147A patent/AU2021226147A1/en active Pending
-
2022
- 2022-09-14 ZA ZA2022/10224A patent/ZA202210224B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Altunay et al. | HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging | |
| Wei et al. | ImmunoPET: concept, design, and applications | |
| CN108136012B (zh) | 靶向分子的抗原结合构建体 | |
| JP5185815B2 (ja) | 抗ｃｄ７１モノクローナル抗体および悪性腫瘍細胞を治療するためのその使用 | |
| Hong et al. | Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105 | |
| EP3049118B1 (en) | Anti-cd146 monoclonal antibody | |
| Levêque et al. | Pharmacokinetics of therapeutic monoclonal antibodies used in oncology | |
| US11679166B2 (en) | Anti-human MUC1 antibody Fab fragment | |
| JP7553633B2 (ja) | Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体 | |
| US11667724B2 (en) | Anti-human CEACAM5 antibody Fab fragment | |
| JP2002544173A (ja) | 抗ｃｄ２２抗体を用いたｂ細胞悪性腫瘍の免疫療法 | |
| WO2002060955A2 (en) | Modified antibodies and methods of use | |
| AU2002240120A1 (en) | Modified antibodies and methods of use | |
| CN101432307A (zh) | 显示cd44表面表达的细胞的细胞毒性介导 | |
| JP2023537002A5 (enExample) | ||
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| Vorobyeva et al. | Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy | |
| Hoppmann et al. | Radiolabeled affibody-albumin bioconjugates for HER2 positive cancer targeting | |
| EP4341265A1 (en) | Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use | |
| TW202144377A (zh) | 用於分子接合或工程化的縱排重複癌症靶向胜肽及其於癌症診療中的用途 | |
| JP2024517879A5 (enExample) | ||
| US20180126001A1 (en) | Antibody-vaccine engineered constructs (avec) | |
| US20080031873A1 (en) | Humanized monoclonal antibody 31.1 as an anticancer agent | |
| US20140341810A1 (en) | Antagonists for abdominal vasopressin v2 receptor and uses thereof | |
| JP2002523381A (ja) | Ｅｐｃｒを使用する大きい血管の内皮への分子標的化 |